Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mayocp.2021.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mycosis Fungoides Presenting With Multiple Tumors on the Face.
Cureus
May 2024
Dermatology, University of Occupational and Environmental Health, Kitakyushu, JPN.
An 84-year-old female experienced progressive erythema on her limbs and chest over the past year. Initially managed with topical steroids, the erythema eventually spread throughout her body, forming erosions. A biopsy confirmed the diagnosis of mycosis fungoides (MF) (Stage IIB, T2bN0M0B0).
View Article and Find Full Text PDFSezary Syndrome: A Case Report and Review of Current Therapeutics.
Cureus
April 2024
Hematology/Oncology, Infirmary Health System, Mobile, USA.
Sezary syndrome (SS) is a rare but aggressive type of cutaneous T-cell lymphoma (CTCL). Patients with SS have characteristic skin lesions (erythroderma) and a leukemic phase. The rash associated with CTCLs can often mimic common benign skin conditions such as psoriasis, atopic dermatitis, etc.
View Article and Find Full Text PDFSuccessful Treatment of Bexarotene-Induced Central Hypothyroidism.
JCEM Case Rep
April 2024
Department of Endocrinology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
The synthetic retinoid bexarotene (BXT), used in the treatment of cutaneous T-cell lymphoma (CTCL), has been associated with central hypothyroidism due to suppression of thyrotropin (TSH) secretion and upregulation of peripheral thyroxine (T4) and triiodothyronine (T3) metabolism. We present a case of a 41-year-old man with CTCL who developed central hypothyroidism within 1 month of receiving BXT. He required sequential uptitration of levothyroxine (LT4) over 15 months, and free T4 (FT4) and total T3 levels were normalized by a daily regimen of LT4 600 mcg and liothyronine (LT3) 15 mcg.
View Article and Find Full Text PDFChronic Radiation Dermatitis Secondary to Narrow-Band Ultraviolet B Therapy in a Patient With Primary Cutaneous CD8 + T-Cell Lymphoma With Cytotoxic Granules.
Am J Dermatopathol
May 2024
Division of Dermatology, Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA.
Conventional therapies for CD8 + cutaneous T-cell lymphoma include topical steroids, topical nitrogen mustard, topical bexarotene, ultraviolet B therapy, psoralen and ultraviolet A therapy, local radiotherapy, and interferon alfa; however, these treatments are often found to be ineffective. Presented is a case of CD8 + cutaneous T-cell lymphoma with near-complete response to narrow-band ultraviolet therapy because of chronic radiation dermatitis initially believed to be possible progression of a CD8 + cutaneous epidermotropic cytotoxic T-cell lymphoma.
View Article and Find Full Text PDFAn occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
Ther Adv Hematol
March 2024
Department of Dermatology, Caen-Normandie University Hospital, Avenue de la Côte de Nacre, 14003 Caen, France.
Article Synopsis
- Mogamulizumab is a monoclonal antibody that targets CCR4, effective in treating cutaneous T-cell lymphoma like mycosis fungoides and Sézary syndrome, particularly in patients who haven't responded to prior treatments.
- Adverse effects include rash, which can resemble disease progression but may indicate better treatment outcomes in some cases, especially in Sézary syndrome.
- A case of a 72-year-old woman showed a complete response to mogamulizumab despite developing eosinophilic folliculitis and lymphopenia, highlighting the need for careful monitoring and further studies on treatment effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!